H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 19.11 CNY -0.78% Market Closed
Market Cap: 11.5B CNY
Have any thoughts about
Hualan Biological Bacterin Inc?
Write Note

Hualan Biological Bacterin Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hualan Biological Bacterin Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
H
Hualan Biological Bacterin Inc
SZSE:301207
Other Long-Term Assets
ÂĄ219.6m
CAGR 3-Years
9%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Long-Term Assets
ÂĄ304.3m
CAGR 3-Years
-29%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Other Long-Term Assets
ÂĄ8.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Long-Term Assets
ÂĄ405.6m
CAGR 3-Years
39%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Other Long-Term Assets
ÂĄ132.9m
CAGR 3-Years
-37%
CAGR 5-Years
-12%
CAGR 10-Years
9%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Long-Term Assets
ÂĄ1.2B
CAGR 3-Years
24%
CAGR 5-Years
38%
CAGR 10-Years
32%
No Stocks Found

Hualan Biological Bacterin Inc
Glance View

Market Cap
11.5B CNY
Industry
Biotechnology

Hualan Biological Bacterin Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Xinxiang, Henan and currently employs 917 full-time employees. The company went IPO on 2022-02-18. Hualan Biological Bacterin Inc is a China-based company specializing in the research, development, production and sales of human vaccines. The firm's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The firm's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The firm's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.

Intrinsic Value
30.12 CNY
Undervaluation 37%
Intrinsic Value
Price
H

See Also

What is Hualan Biological Bacterin Inc's Other Long-Term Assets?
Other Long-Term Assets
219.6m CNY

Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Other Long-Term Assets amounts to 219.6m CNY.

What is Hualan Biological Bacterin Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
27%

Over the last year, the Other Long-Term Assets growth was 3%. The average annual Other Long-Term Assets growth rates for Hualan Biological Bacterin Inc have been 9% over the past three years , 27% over the past five years .

Back to Top